Cancer Biology & Medicine

►►Submit your paper by clicking the ABOVE RED TAG "ONLINE SUBMISSION".

 

►►Very important notification on publication fee

Effective February 2019, Cancer Biology & Medicine, as an open access journal, will charge a reasonable publication fee of $1,500/¥10,000 for each accepted article (all article types). No fees will be charged for invited articles.


Cancer Biology & Medicine

Cancer Biology & Medicine is a peer-reviewed open-access journal published by the Chinese Anti-cancer Association (CACA), which is the leading professional society of oncology in China. Published quarterly, the journal provides innovative and significant information on the biological basis of cancer, cancer microenvironment, translational cancer research, and all aspects of clinical cancer research. The journal also publishes significant perspectives on indigenous cancer types in China. The scope covers the following topics:

● Cancer genetics

● Cancer and stem cell biology

● Molecular and clinical immunology

● Cancer prevention and epidemiology

● Cancer biomarkers

● Radiation oncology

● Oncology clinical trials

● Mechanisms of drug sensitivity and resistance

● Targeted therapy and immunotherapy

● Multidisciplinary treatment and personalized medicine

Author Benefits

● Easy submission via online system

● Efficient and professional peer review

● Rapid pre-print online publication

● No charge for publication and open access

● International visibility-All full texts are free in PubMed Central

 

Announcements

 

Publication of the 3rd issue in 2019

 

Several invited reviews were included in the 3rd issue, which focused on Warburg effect and related proton homeostasis in proliferating cells (Prof. Binghui Li, et al.); tissue specificity of DNA damage response and tumorigenesis (Prof Mo Li, et al.); targeted intervention in malignancy (Prof. Yukun Cui, et al.); and nanotechnology in cancer immunotherapy (Prof. Ning Gu, et al.) as well. Except for the above reviews on basic medicine, Prof. Masatoshi Makuuchi contributed a review on precision surgery for primary liver cancer. As a matter of fact, other reviews also brought some novel academic viewpoints on cancer translational researches.

 

Although all the original articles are worthy of reading, we still recommend two papers on cancer epidemiology, namely, “Prevalence and clinical significance of pathogenic germline BRCA1/2 mutations in Chinese non-small cell lung cancer patients” by Prof. Chengping Hu et al. and “Incidence, distribution of histological subtypes and primary sites of soft tissue sarcoma in China” by Wanqing Chen et al. Whereas, other researches displayed advances in aspects of molecular mechanisms and application in cancer diagnosis and treatment, which includes many types of malignancies, such as melanoma, gastric

cancer , lymphoma, colorectal cancer , non-small cell lung cancer, soft tissue sarcoma, breast cancer, papillary thyroid microcarcinoma, glioblastoma, hepatocellular carcinoma, and so on.

 

We hope the content of this issue will greatly benefit your research and clinical practice. Thank you for your attention and welcome to submit your work to Cancer Biology & Medicine.

 
Posted: 2019-08-14
 

NEW IMPACT FACTOR 4.467

 
According to the Journal Citation Reports (2019), the IMPACT FACTOR (2018) of Cancer Biology & Medicine is 4.467, locating in Q1 area of Medicine, Research & Experimental category (ranking 33/136) and Q2 area of Oncology category (ranking 66/229).
 
Posted: 2019-06-25
 
More Announcements...

Breast Cancer Collection (2017-2019)

The collection includes all the papers on breast cancer published by Cancer Biology & Medicine in 2017-2019.

Table of Contents



OUR FRIENDS